Arazu Wanna
Aurora, CONPI 1487913497
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 30.5% of the total. 2023 is the largest year on record at $521, 3.9 times the $134 reported in 2019.
Across 86 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$511
- AstraZeneca$221
- Novo Nordisk$169
- Johnson & Johnson$131
- Boehringer Ingelheim$93
- Lilly USA, LLC$78
- plus $469 from 13 others
What the payments were for
- Food & beverage$1,672100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $511 |
| AstraZeneca | 15 | $221 |
| Novo Nordisk | 10 | $169 |
| Johnson & Johnson | 1 | $131 |
| Boehringer Ingelheim | 5 | $93 |
| Lilly USA, LLC | 5 | $78 |
| Merck | 4 | $63 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Astellas Pharma US Inc | 2 | $52 |
| GSK | 3 | $47 |
| Pfizer | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| Amgen | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Lifescan, Inc. | 1 | $32 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| IBSA Pharma Inc. | 1 | $15 |
| Gilead | 1 | $13 |
| Philips North America LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monarch Platform$131
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 15 | $125 |
| Rosuvastatin Calcium | 18 | $52 |
| Hydrochlorothiazide | 15 | $45 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.